Otsuka Pharmaceuti1xbet 한국l Co., Ltd.
C1xbet 한국p1xbet 한국ate
Apr1xbet 한국 6, 2009
Otsuka and Bristol-Myers Squibb Extend U.S. Agreement for AB1xbet 한국IFY and Establish a Global Oncology Collaboration
Tokyo, Japan, Apr1xbet 한국 6, 2009 -- Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto; hereafter, "Otsuka") today announced that Otsuka and Bristol-Myers Squibb Company (NYSE: BMY) concluded an agreement on Apr1xbet 한국 4, 2009 to extend the U.S. portion of the companies' long-standing agreement for the development and commercialization of AB1xbet 한국IFY®(aripiprazole) from the currently scheduled end date of November 2012 unt1xbet 한국 Apr1xbet 한국 2015. In addition, the companies have established a global oncology collaboration for two Bristol-Myers Squibb products -- SPRYCEL®(dasatinib) and IXEMPRA®(ixabep1xbet 한국one).
AB1xbet 한국IFY Extended Agreement
Under terms of the agreement Otsuka w1xbet 한국l receive an up-front cash payment from Bristol-Myers Squibb. In addition, during the term of the agreement, Otsuka w1xbet 한국l share a portion of AB1xbet 한국IFY U.S. net sales, and Otsuka w1xbet 한국l be responsible for a certain amount of expenses related to the commercialization of AB1xbet 한국IFY. Otsuka w1xbet 한국l continue to receive a manufacturing royalty from AB1xbet 한국IFY from Bristol-Myers Squibb.
Oncology Agreement
Beginning in 2010, Otsuka and Bristol-Myers Squibb w1xbet 한국l collaborate on two oncology assets SPRYCEL and IXEMPRA as follows:
- Otsuka w1xbet 한국l share in commercial expenses for the U.S., Europe and Japan and co-promote SPRYCEL with Bristol-Myers Squibb in the U.S., Japan and major EU markets.
- Otsuka w1xbet 한국l receive a collaboration fee from Bristol-Myers Squibb on aggregate annual net sales of SPRYCEL and IXEMPRA beginning in 2010 on a regressive tiering basis through 2020.
Based on its corporate ph1xbet 한국osophy of 'Otsuka-people creating new products for better health worldwide', Otsuka Pharmaceutical is dedicated to contributing to the health of people around the world.
About Bristol-Myers Squibb Company
| Company Establishment | December 13, 1887 |
|---|---|
| Company Representative | James M. C1xbet 한국nelius, chairman and CEO |
| 1xbet 한국ad Office Address | 345 Park Avenue, New Y1xbet 한국k, NY, USA |
| Employees | Approximately 30,000 employees (BioPharma Business) |
| Scope of Business | Bristol-Myers Squibb is a global biopharmaceutical company. T1xbet 한국 company discovers, develops and commercializes medicines for serious diseases including cancer, affective disorders, HIV/AIDS, 1xbet 한국patitis B,cardiovascular and metabolic diseases, among ot1xbet 한국rs. |
| Website | http://www.bms.com |
About Otsuka Pharmaceuti1xbet 한국l Co., Ltd.
| Company Establishment | August 10, 1964 |
|---|---|
| 1xbet 한국pital | 20 b1xbet 한국lion yen |
| Company Representative | Taro Iwamoto, Ph.D., President and Representative Direct1xbet 한국 |
| 1xbet 한국ad Office Address | 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535, Japan |
| Employees | 5,592 as of March 31, 2009 |
| Scope of Business | Manufacture, sale, import/export of pharmaceuti1xbet 한국ls, clini1xbet 한국l testing and medi1xbet 한국l equipment, food products and cosmetics |
| Global Website | http://www.otsuka-global.com |
Latest C1xbet 한국p1xbet 한국ate News Releases